https://doi.org/10.4081/mm.2013.2257

The Genotype MTBDRplus ver. 2.0 test as a quick indicator of resistance to rifampicin and isoniazid in Mycobacterium tuberculosis strains

Vol. 28 No. 2 (2013)
Submitted: 27 January 2014
Accepted: 27 January 2014
Published: 31 August 2013
Tuberculosis, Antitubercular drugs, Multidrug resistant, Genotype MTBDRplus
Abstract Views: 1055
PDF: 620
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Salvatore Nisticò
snistico1@virgilio.it
Laboratorio di Microbiologia e Virologia, P.O. di Lamezia Terme A.S.P. di Catanzaro, Italy.
Paola Magno
Laboratorio di Microbiologia e Virologia, P.O. di Lamezia Terme A.S.P. di Catanzaro, Italy.
Annelisa Borelli
Laboratorio di Microbiologia e Virologia, P.O. di Lamezia Terme A.S.P. di Catanzaro, Italy.
Vincenzina Caruso
Laboratorio di Microbiologia e Virologia, P.O. di Lamezia Terme A.S.P. di Catanzaro, Italy.
Vilma Villella
Laboratorio di Microbiologia e Virologia, P.O. di Lamezia Terme A.S.P. di Catanzaro, Italy.
Lorenzo Antonio Surace
Dispensario Funzionale Aziendale A.S.P. di Catanzaro, Italy.
Laura Pontoriero
Dispensario Funzionale Aziendale A.S.P. di Catanzaro, Italy.
Domenico Lucchino
U.O. di Malattie Infettive, P.O. di Lamezia Terme A.S.P. di Catanzaro, Italy.
Giuseppina Berardelli
U.O. di Malattie Infettive, P.O. di Lamezia Terme A.S.P. di Catanzaro, Italy.
Ginafranco Griffo
U.O. di Malattie Infettive, P.O. di Lamezia Terme A.S.P. di Catanzaro, Italy.
Domenico Caruso
Laboratorio di Microbiologia e Virologia, P.O. di Lamezia Terme A.S.P. di Catanzaro, Italy.
Rosa Anna Leone
Laboratorio di Microbiologia e Virologia, P.O. di Lamezia Terme A.S.P. di Catanzaro, Italy.
Tuberculosis is still a global emergency and a major public health problem, in some cases related to the appearance of strains of multi drug resistance (MDR) and extensive drug resistance (XDR) Mycobacterium tuberculosis complex.The correct determination of antibiotic sensitivity profiles is therefore crucial to carry out appropriate treatment aimed to decrease the infectivity of each patient and to reduce mortality. The poor adherence to treatment by the patient or the use of therapies based on a single drug, as a result of incorrect requirements, promote the development of drug-resistance. Have some time on the market of molecular diagnostic tests that allow, quickly and directly from biological sample to search for resistance genes some key drugs of anti-TB therapy (Rifampicin and Isoniazid). One of the tests in question is the Genotype MTBDRplus ver 2.0 which can reveal the presence of genes for resistance to Isoniazid (INH) and Rifampin (RMP).The loci analyzed are those corresponding to the rpoB gene for rifampicin, katG and inhA for isoniazid. Our study is based on the analysis of 83 strains of tubercular Mycobacteria identified and isolated from patients with tuberculosis disease and subjected to the tests sensitivity, searching for mutations and phenotypic susceptibility testing for Rifampicin and Isoniazid.The comparison of the results has shown that the results obtained using the Genotype MTBDRplus ver 2.0 test, were similar to the results obtained by the traditional susceptibility testing.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

How to Cite

Nisticò, S., Magno, P., Borelli, A., Caruso, V., Villella, V., Surace, L. A., Pontoriero, L., Lucchino, D., Berardelli, G., Griffo, G., Caruso, D., & Leone, R. A. (2013). The Genotype MTBDRplus ver. 2.0 test as a quick indicator of resistance to rifampicin and isoniazid in Mycobacterium tuberculosis strains. Microbiologia Medica, 28(2). https://doi.org/10.4081/mm.2013.2257

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.